Can Catalyst Pharmaceutical cover its short-term obligations?

Its current ratio is 7.10 — current assets exceed current liabilities.

Where does Catalyst Pharmaceutical's balance sheet data come from?

Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Catalyst Pharmaceutical CPRX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$709.17M+37.0%	$517.55M+276%	$137.64M-53.9%	$298.4M+74.0%
Accounts receivable, net	$126.48M+93.2%	$65.48M+22.4%	$53.51M+413%	$10.44M+57.7%
Inventories	$37.17M+90.2%	$19.54M+24.9%	$15.64M+130%	$6.81M-13.5%
Prepaid expenses and other current assets	$21.22M+0.8%	$21.04M+67.8%	$12.54M+143%	$5.17M+18.8%
Total current assets	$894.03M+43.4%	$623.61M+184%	$219.33M-31.6%	$320.81M+52.7%
Property and equipment, net	$1.04M-23.4%	$1.35M+13.3%	$1.2M+41.1%	$847K-11.7%
Operating lease right-of-use assets	$1.94M-13.2%	$2.23M-11.1%	$2.51M-9.5%	$2.77M-8.2%
Intangible assets, net	$131.67M-16.0%	$156.67M-19.3%	$194.05M+498%	$32.47M—
Deferred tax assets	$52.77M+14.8%	$45.98M+25.8%	$36.54M+95.0%	$18.74M-20.9%
Total investments	$22.54M+4.5%	$21.56M+30.8%	$16.49M—	$0—
Total assets	$1.1B+29.7%	$851.41M+81.1%	$470.11M+25.2%	$375.63M+58.0%
Accounts payable	$11.2M-32.5%	$16.59M+12.2%	$14.8M+272%	$3.98M+43.6%
Accrued expenses	$135.95M+30.6%	$104.09M+69.9%	$61.27M+14.3%	$53.61M+121%
Operating lease liabilities, current	$437K+8.7%	$402K+8.9%	$369K+9.5%	$337K+9.4%
Total current liabilities	$147.15M+21.9%	$120.68M+58.7%	$76.06M+32.1%	$57.59M+113%
Operating lease liabilities, non-current	$2.35M-15.6%	$2.79M-12.6%	$3.19M-10.4%	$3.56M-8.7%
Finance Lease Liabilities (Total)	$0—	$0—	——	——
Operating Lease Liabilities (Total)	$2.79M-12.6%	$3.19M-10.4%	$3.56M-8.7%	$3.89M-7.3%
Finance lease liabilities	$0—	$0—	——	——
Other non-current liabilities	$209K-33.7%	$315K-89.4%	$2.98M-78.8%	$14.06M—
Total liabilities	$149.71M+21.0%	$123.78M+50.5%	$82.23M+9.3%	$75.21M+143%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	$123K+1.7%	$121K+13.1%	$107K+1.9%	$105K+1.9%
Additional paid-in capital	$479.96M+8.5%	$442.29M+66.0%	$266.49M+6.4%	$250.43M+7.4%
Retained earnings	$474.19M+66.3%	$285.16M+135%	$121.27M+143%	$49.86M+290%
Accumulated other comprehensive income (loss)	$0-100%	$64K+357%	$14K-41.7%	$24K+116%
Total stockholders' equity	$954.27M+31.1%	$727.63M+87.6%	$387.88M+29.1%	$300.42M+45.2%
Total liabilities and stockholders' equity	$1.1B+29.7%	$851.41M+81.1%	$470.11M+25.2%	$375.63M+58.0%
Equity Securities (FV-NI) - Non-Current	$22.54M+4.5%	$21.56M+30.8%	$16.49M—	$0—
Equity Securities (Non-Current)	$22.54M+4.5%	$21.56M+30.8%	$16.49M—	$0—
Net Investment in Lease	$1.94M-13.2%	$2.23M-11.1%	$2.51M-9.5%	$2.77M-8.2%
Deferred tax assets	$52.77M+14.8%	$45.98M+25.8%	$36.54M+95.0%	$18.74M-20.9%
Intangible assets — net	$131.67M-16.0%	$156.67M-19.3%	$194.05M+498%	$32.47M—
Operating lease right-of-use assets	$1.94M-13.2%	$2.23M-11.1%	$2.51M-9.5%	$2.77M-8.2%
Operating Lease Right-of-Use Assets in Other Assets	$1.94M-13.2%	$2.23M-11.1%	$2.51M-9.5%	$2.77M-8.2%
Other Commercial Liabilities	$135.95M+30.6%	$104.09M+69.9%	$61.27M+14.3%	$53.61M+121%
Accrued Liabilities, Current	$135.95M+30.6%	$104.09M+69.9%	$61.27M+14.3%	$53.61M+121%
Total debt	$2.79M-12.6%	$3.19M-10.4%	$3.56M-8.7%	$3.89M-7.3%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$123K+1.7%	$121K+13.1%	$107K+1.9%	$105K+1.9%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Catalyst Pharmaceutical cover its short-term obligations?: Its current ratio is 7.10 — current assets exceed current liabilities.
Where does Catalyst Pharmaceutical's balance sheet data come from?: Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.